.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Daiichi Sankyo
Covington
Chubb
Chinese Patent Office
McKesson
Baxter
Express Scripts
Argus Health
Farmers Insurance

Generated: July 21, 2017

DrugPatentWatch Database Preview

Meloxicam - Generic Drug Details

« Back to Dashboard

What are the generic sources for meloxicam and what is the scope of meloxicam patent protection?

Meloxicam
is the generic ingredient in three branded drugs marketed by Taro, Aurobindo Pharma, Yung Shin Pharm, Breckenridge Pharm, Zydus Pharms Usa, Mylan, Roxane, Unichem, Strides Pharma, Cipla Ltd, Boehringer Ingelheim, Corepharma, Dr Reddys Labs Inc, Glenmark Generics, Iroko Pharms Llc, Yabao Pharm, Frontida Biopharm, Teva Pharms, Sun Pharm Inds Inc, Puracap Pharm, Cr Double Crane, Lupin Pharms, and Apotex Inc, and is included in twenty-five NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Meloxicam has forty-one patent family members in thirty-one countries.

There are twenty-two drug master file entries for meloxicam. Fifty-three suppliers are listed for this compound.

Summary for Generic Name: meloxicam

Tradenames:3
Patents:4
Applicants:23
NDAs:25
Drug Master File Entries: see list22
Suppliers / Packagers: see list53
Bulk Api Vendors: see list86
Clinical Trials: see list64
Patent Applications: see list8,038
Therapeutic Class:Anti-inflammatory Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:meloxicam at DailyMed

Pharmacology for Ingredient: meloxicam

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Yabao Pharm
MELOXICAM
meloxicam
TABLET;ORAL077933-001Jul 19, 2006DISCNNoNo► Subscribe► Subscribe
Taro
MELOXICAM
meloxicam
TABLET;ORAL078102-002Nov 7, 2006ABRXNoNo► Subscribe► Subscribe
Strides Pharma
MELOXICAM
meloxicam
TABLET;ORAL077928-002May 13, 2009ABRXNoNo► Subscribe► Subscribe
Yabao Pharm
MELOXICAM
meloxicam
TABLET;ORAL077933-002Jul 19, 2006DISCNNoNo► Subscribe► Subscribe
Mylan
MELOXICAM
meloxicam
TABLET;ORAL077923-002Jul 19, 2006ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: meloxicam

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,682,747 Process for preparing an oral suspension of a pharmaceutical substance► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: meloxicam

Country Document Number Estimated Expiration
Argentina016196► Subscribe
Turkey200002772► Subscribe
Hong Kong1034184► Subscribe
World Intellectual Property Organization (WIPO)9949845► Subscribe
Japan2002509875► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Moodys
Cerilliant
Boehringer Ingelheim
Merck
Fuji
McKesson
Medtronic
Fish and Richardson
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot